Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches
Table 4
Summary of the proportion of initial and recurrent of IDH-wildtype and IDH-mutant glioblastoma patient tumours that had SNVs that could be assigned as potentially clinically actionable.
For particular genetic alterations, the proportion of glioblastomas (n = 47) with alterations in those genes, as recorded by Sahm et al. [30], is also provided. Also summarised are available and new therapeutic agents currently on trial in clinical studies targeting molecular aberrations.